Fedratinib | Interleukin Related interleukin-related.com

Product Name :
Fedratinib

Search keywords :
Fedratinib

drugId :
null

Target Vo:
Tyrosine-protein kinase JAK2

Target Vo Short Name :
JAK2

Moa_Name:
Tyrosine-protein kinase JAK2 inhibitors

First Approval Country :
United States

First Approval Date Filter:
2019

Origin Company_Name :
Sanofi

Active Company_Name :
Bristol-Myers Squibb Company

Active Indication_Name:
Primary Myelofibrosis

In Active Indication_Name:
Kidney Diseases

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
beta Catenin Antibody (YA936) custom synthesis
IL-10 Antibody Protocol
Phospho-c-Met (Tyr1349) Antibody: Phospho-c-Met (Tyr1349) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Phospho-c-Met (Tyr1349). It can be used for WB,IP assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts